← Today’s ReceiptsSource pending
Public-record receiptR-ARSource pending
J. Hill disclosed SELL $PFE
Here’s the public record: who traded, what they disclosed, when it happened, how late it appeared, and what context is attached.
Trade range
$100K – $250K
Filed
2026-01-26
Trade date
2025-12-31
Disclosure lag
26 days after trade
Why this receipt matters
A quick read before you share it.
These are factual context points from the receipt and linked public-record data. They explain why the disclosure may be worth opening, not whether anyone acted improperly.
1The disclosure is tracked with source status pending, so treat it as a record to verify rather than a finished source trail.
2The filing appeared 26 days after trade, which helps separate trade timing from filing timing.
3The disclosed range is $100K – $250K, which is the public reporting band rather than an exact profit or loss figure.
44 nearby same-ticker disclosures appeared in the surrounding 30-day window.
5Committee context is available for J. Hill, but PoliWealth treats it as context - not proof of intent or wrongdoing.
6Related public-record context includes 33 lobbying filings and 1 federal contract record.
Source
source pending
Source: indexed congressional disclosure; official source link pending · filed 2026-01-26 · disclosed 26d after transaction
Market context
Pfizer Inc.
Sector: Healthcare
Factual flags
- 33 lobbying filings linked to this ticker.
- 1 federal contract record linked to this ticker.
- 4 nearby same-ticker disclosures in the surrounding 30-day window.
- Traded PFE 23d before lobbying filing by PFIZER INC. ($2,810,000)
- Trade upper bound: $250,000
- 4 trades filed on 2026-01-26 (batch dump)
Member trail
J. Hill
U.S. House · AR-2
House Permanent Select Committee on IntelligenceHouse Committee on Financial Services
Ticker trail
$PFE
Pfizer Inc.
Follow this tickerAlert me when this ticker gets a new congressional receipt. This page reports public disclosures and factual context only. It does not determine intent, is not an accusation, and is not investment advice.